Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice

Claudia Palladino1, María Luisa Navarro Gómez, Pere Soler-Palacín

  • 1aResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal bSección de Enfermedades Infecciosas, Servicio de Pediatría, Hospital General Universitario 'Gregorio Marañón', Madrid cUnitat de Patologia Infecciosa i Immunodeficiències de Pediatria, Hospital Universitari Vall d'Hebron, Institut de Recerca Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona dServicio de Infecciosas Pediátricas, Hospital Universitario 'Doce de Octubre', Madrid eLaboratorio InmunoBiología Molecular, Hospital General Universitario 'Gregorio Marañón', Instituto de Investigación Sanitaria 'Gregrio Marañón' (IiSGM), Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid fUnidad de Estadística y Bioinformática. Institut de Recerca Vall d'Hebron, Barcelona gUnidad Medicina Interna Pediá[Combining Acute Accent]trica, Hospital Infantil Universitario 'Virgen del Rocío', Seville hUnidad Servicio de Pediatría, Hospital Universitario Germans Trias i Pujol Badalona iUnidad de Infectología e Inmunodeficiencias, Servicio de Pediatría, Hospital Regional Universitario 'Carlos Haya', Málaga jUnitat d'Infectologia, Servei de Pediatria; Hospital Sant Joan de Déu, Universitat de Barcelona kPediatric Service, Universitat Autónoma de Barcelona, Hospital del Mar, Barcelona lUnidad de Infectología Pediatrica, Hospital de Cruces, Bilbao mServicio de Enfermedades Infecciosas, Hospital Ramón y Cajal nUnit of Viral Infection and Immunity, National Center for Microbiology, Institute of Health Carlos III, Majadahonda. Madrid, Spain.

AIDS (London, England)
|November 7, 2015
PubMed

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
462
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
373
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
712
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
330
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
751
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
748